What is the recommended enoxaparin (low‑molecular‑weight heparin) dose and dosing interval for a patient weighing 55 kg?

Enoxaparin Dosage for 55kg Patient

For a 55kg patient, the recommended enoxaparin dose is 55mg subcutaneously every 12 hours for treatment indications, or 40mg subcutaneously once daily for prophylaxis, with specific adjustments based on clinical context (acute coronary syndrome, VTE treatment, or prophylaxis) and renal function.

Clinical Context Determines Dosing

The appropriate enoxaparin dose for a 55kg patient varies significantly based on the indication:

For Acute Coronary Syndromes (ACS)

Initial therapy: 1 mg/kg subcutaneously every 12 hours = 55mg every 12 hours 1, 2, 1

• If creatinine clearance <30 mL/min: reduce to 1 mg/kg once daily = 55mg once daily 1, 2
• With fibrinolytic therapy in patients <75 years: 30mg IV bolus, followed in 15 minutes by 1 mg/kg subcutaneously every 12 hours (maximum 100mg for first 2 doses) = 55mg every 12 hours 1, 2
• With fibrinolytic therapy in patients ≥75 years: no bolus, 0.75 mg/kg subcutaneously every 12 hours (maximum 75mg for first 2 doses) = 41mg every 12 hours 1, 2

For VTE Treatment

Standard therapeutic dosing: 1 mg/kg every 12 hours = 55mg every 12 hours 3

• Alternative once-daily regimen: 1.5 mg/kg once daily = 82.5mg once daily 3
• With renal impairment (CrCl <30 mL/min): 1 mg/kg once daily = 55mg once daily 3

For VTE Prophylaxis

Standard prophylactic dose: 40mg subcutaneously once daily 3, 4

This fixed dose applies regardless of the 55kg weight for most prophylaxis scenarios 3, 4.

Important Considerations for Low-Weight Patients

Prophylactic Dosing Concerns

A 55kg patient sits at a critical threshold where standard prophylactic dosing may result in higher-than-expected anti-Xa levels:

• Research demonstrates that patients weighing ≤55kg receiving standard 40mg daily prophylaxis achieve mean anti-Xa activity of 0.54±0.18 IU/mL, with 60% exhibiting levels ≥0.5 IU/mL 5
• Patients weighing ≤45kg show significantly higher anti-Xa activity (0.61±0.18 IU/mL) with an 8-fold increased odds of anti-Xa ≥0.5 IU/mL 5
• For prophylaxis in a 55kg patient, 40mg daily remains appropriate, but consider 30mg daily if weight is closer to 45kg or if bleeding risk is elevated 5, 6

Therapeutic Dosing Precision

For treatment indications, weight-based dosing at 1 mg/kg provides more predictable anticoagulation:

• The 55mg dose (1 mg/kg × 55kg) falls within standard therapeutic ranges
• No dose reduction is needed based on weight alone unless renal impairment is present
• Monitor anti-Xa levels if available, targeting 0.5-1.0 IU/mL for treatment (drawn 4 hours post-dose) 3

Renal Function Adjustment Algorithm

Critical decision point: Assess creatinine clearance before dosing

1. CrCl ≥30 mL/min: Use standard weight-based dosing as above
2. CrCl <30 mL/min:
   • For treatment: 1 mg/kg once daily = 55mg once daily 1, 3, 2
   • For prophylaxis: 30mg once daily (per package insert guidance for severe renal impairment) 4
3. Contraindication: Fondaparinux (alternative anticoagulant) is contraindicated if CrCl <30 mL/min 1, 2

Common Pitfalls to Avoid

• Do not use fixed 30mg twice daily dosing for treatment indications in a 55kg patient—this underdoses at 0.55 mg/kg per dose
• Do not automatically reduce prophylactic doses to 30mg daily in all 55kg patients; reserve this for those <50kg or with elevated bleeding risk 5, 6
• Do not switch between enoxaparin and UFH during the same hospitalization due to increased bleeding risk 7
• Do not use fondaparinux to support PCI as it increases catheter thrombosis risk 1, 2, 1

Monitoring Recommendations

While routine anti-Xa monitoring is not required for most patients, consider monitoring in:

• Patients at extremes of body weight (<50kg or >150kg)
• Severe renal impairment (CrCl 15-30 mL/min)
• Pregnancy
• Recurrent thrombosis despite therapy

Target anti-Xa levels:

• Prophylaxis: 0.2-0.5 IU/mL (drawn 4 hours post-dose)
• Treatment: 0.5-1.0 IU/mL for twice-daily dosing; 1.0-2.0 IU/mL for once-daily dosing 3